HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The GnRH agonists in the treatment of uterine leiomyomas.

Abstract
The observation that fibroids regress after the menopause has led many authors to use GnRH agonists to obtain a reversible state of hypoestrogenism in patients with this tumor. In all the studies performed GnRH agonists have been found effective in inducing a marked regression of fibroids and resolution of the related symptoms. The only serious side effect reported has been a decrease of bone mineral density, which necessarily limits the duration of treatment. Fibroids have been observed to grow back in almost all patients a few months after suspension of treatment, and this limits the indications for the use of GnRH agonist in the treatment of this condition. GnRH agonists are the treatment of choice, however, in inoperable patients and in those with severe anemia, whereas further studies are needed to better define their use in preoperative treatment and in women in perimenopausal age.
AuthorsS Bianchi, L Fedele
JournalActa Europaea fertilitatis (Acta Eur Fertil) 1989 Jan-Feb Vol. 20 Issue 1 Pg. 5-10 ISSN: 0587-2421 [Print] Italy
PMID2675524 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Gonadotropin-Releasing Hormone
Topics
  • Antineoplastic Agents (therapeutic use)
  • Female
  • Gonadotropin-Releasing Hormone (analogs & derivatives, therapeutic use)
  • Humans
  • Leiomyoma (drug therapy)
  • Neoplasm Recurrence, Local
  • Uterine Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: